Trial · NCT00064337

S0115, High-Dose Melphalan and Autologous Peripheral Stem Cell Transplantation in Treating Patients With Multiple Myeloma or Primary Systemic Amyloidosis

NCT00064337, Phase 2, Completed, SWOG Cancer Research Network; results first posted 2017-11-06

3 sourcestrials-2026-11-12-0.5.0

Cite this record

ConductScience Library. S0115, High-Dose Melphalan and Autologous Peripheral Stem Cell Transplantation in Treating Patients With Multiple Myeloma or Primary Systemic Amyloidosis. Trials, record NCT00064337. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT00064337

On this page

Trial

As registered on ClinicalTrials.gov, in the graph's capture of the registry.

Title: S0115, High-Dose Melphalan and Autologous Peripheral Stem Cell Transplantation in Treating Patients With Multiple Myeloma or Primary Systemic Amyloidosis
NCT number: NCT00064337
Status: Completed
Phases: Phase 2
Enrollment: 104 participants, actual
Lead sponsor: SWOG Cancer Research Network
Conditions: Multiple Myeloma, Plasma Cell Myeloma
Interventions: filgrastim, cyclophosphamide, dexamethasone, melphalan, thalidomide, peripheral blood stem cell transplantation
First posted: 2003-07-09
Last updated: 2018-08-09
Results first posted: 2017-11-06

Source ClinicalTrials.gov

Registered outcomes2

Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.

List	Outcome	Time frame	Description
Primary	Overall Survival	5 years from initial registration, or until death, whichever occurred earlier, on average, about 4.5 years	Time from initial registration until death or date of last contact, whichever occurs first, for up to 5 years from the date of the last patient registration.
Secondary	Hematologic Response	Until off study

Source ClinicalTrials.gov

Outcomes2

Each outcome the trial posted results for, in ClinicalTrials.gov's words.

Type	Outcome	Time frame	Population	Units	Measured as
PRIMARY	Overall Survival	5 years from initial registration, or until death, whichever occurred earlier, on average, about 4.5 years	Eligible and analyzable patients only.	Months	MEDIAN
SECONDARY	Hematologic Response	Until off study		Participants	COUNT_OF_PARTICIPANTS

Source ClinicalTrials.gov

Results by group2

Each measurement the trial posted, group by group, in the words and numbers it posted.

Outcome	Group	Category	Value	Spread	Units
Overall Survival	Treatment		68	95% Confidence Interval 42 to NA	Months
Hematologic Response	Treatment		8		Participants

Source ClinicalTrials.gov

Participant flow9

How many started, completed or left each group, period by period.

Period	Milestone	Group	Participants
PBSCC or Induction/PBSCC	STARTED	Treatment	93
PBSCC or Induction/PBSCC	COMPLETED	Treatment	73
PBSCC or Induction/PBSCC	NOT COMPLETED	Treatment	20
Transplant	STARTED	Treatment	67
Transplant	COMPLETED	Treatment	46
Transplant	NOT COMPLETED	Treatment	21
Maintenance	STARTED	Treatment	13
Maintenance	COMPLETED	Treatment	3
Maintenance	NOT COMPLETED	Treatment	10

Source ClinicalTrials.gov

Adverse events354

Each adverse event the trial posted, group by group: the participants affected out of those at risk.

Type	Event	Organ system	Group	Affected	At risk
other	Febrile neutropenia	Blood and lymphatic system disorders	PBSCC or Induction/PBSCC	2	92
other	Febrile neutropenia	Blood and lymphatic system disorders	Autologous Transplants	20	65
other	Febrile neutropenia	Blood and lymphatic system disorders	Dex/Thal	0	12
other	Hemoglobin	Blood and lymphatic system disorders	PBSCC or Induction/PBSCC	43	92
other	Hemoglobin	Blood and lymphatic system disorders	Autologous Transplants	48	65
other	Hemoglobin	Blood and lymphatic system disorders	Dex/Thal	6	12
other	Lymphatics-Other	Blood and lymphatic system disorders	PBSCC or Induction/PBSCC	5	92
other	Lymphatics-Other	Blood and lymphatic system disorders	Autologous Transplants	8	65
other	Lymphatics-Other	Blood and lymphatic system disorders	Dex/Thal	0	12
other	Cardiac Arrhythmia-Other	Cardiac disorders	PBSCC or Induction/PBSCC	1	92

1 to 10 of 354Source ClinicalTrials.gov

See all 354 adverse events

Adverse event totals9

The totals the trial posted for each group.

Total	Group	Affected	At risk
Total, all-cause mortality	PBSCC or Induction/PBSCC
Total, all-cause mortality	Autologous Transplants
Total, all-cause mortality	Dex/Thal
Total, other adverse events	PBSCC or Induction/PBSCC	83	92
Total, other adverse events	Autologous Transplants	62	65
Total, other adverse events	Dex/Thal	12	12
Total, serious adverse events	PBSCC or Induction/PBSCC	4	92
Total, serious adverse events	Autologous Transplants	3	65
Total, serious adverse events	Dex/Thal	1	12

Source ClinicalTrials.gov

Papers0

The papers the trial lists on ClinicalTrials.gov.

None in this release.

Grants1

The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.

Project	Title	Principal investigators	Organization	Funder	Fiscal years
U10CA032102	Southwest Oncology Group Treatment Grant	BLANKE, CHARLES D.	OREGON HEALTH & SCIENCE UNIVERSITY	NATIONAL CANCER INSTITUTE	1985 to 2013

Source NIH RePORTER

Trial comparisons0

Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.

None in this release.

Tests0

The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.

None in this release.

Data dates

The day each source was copied for this release.

ClinicalTrials.gov: 2026-11-12; ClinicalTrials.gov
Results, from AACT: 2026-03-23; AACT
NIH grant links: 2026-11-13; NIH RePORTER

Sources 3

ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
ClinicalTrials.govNo license stated
NIH RePORTER's clinical studies and project filesPublic domain

Each source's terms

ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
ClinicalTrials.govnone stated
NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this trial from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/trials/v1/NCT00064337

GET https://conductscience.org/api/trials/v1/NCT00064337/events?page=2

API reference For AI assistants